Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Arcturus Therapeutics Inc. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 7 distinct examiners and 6 distinct art units, indicating broad distribution across examination assignments with limited art-unit overlap. Portfolio management should preserve a common technical record while allowing responses to reflect each assignment.
TCHERKASSKAYA, OLGA V is the busiest examiner, with 1 pending matter. No examiner accounts for more than 1 action in the supplied data, so the docket is not concentrated around a single examiner. Counsel should prioritize deadline control, reference tracking, and consistent claim terminology across the 6 art-unit settings.
The relationship between 7 actions, 7 examiners, and 6 art units makes examiner-specific prosecution planning central. Any common specification support or technical explanation should be documented for reuse, while amendments and arguments should remain tied to the particular rejection and art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 2 (29%) |
| §112 only | 1 (14%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
| SHOMER, ISAAC | 1 | 63.1% | +30.5% |
| SASAN, ARADHANA | 1 | 64.6% | +26.0% |
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| MEYERING, SHABANA SHABBEER | 1 | 68.5% | +45.1% |
| CRUM, MARY ABOU NADER | 1 | 39.2% | +63.7% |
| SCHACHERMEYER, SAMANTHA LYNN | 1 | 35.7% | +70.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18660219 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | SHOMER, ISAAC | — |
| 18427625 | METHODS AND COMPOSITIONS FOR QUADRIVALENT INFLUENZA VACCINE | ALLEN, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18984131 | METHOD OF LYOPHILIZING LIPID NANOPARTICLES | TCHERKASSKAYA, OLGA V | — |
| 18660219 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | SHOMER, ISAAC | — |
| 18614077 | LIPID NANOPARTICLES ENCAPSULATION OF LARGE RNA | SASAN, ARADHANA | — |
| 18427625 | METHODS AND COMPOSITIONS FOR QUADRIVALENT INFLUENZA VACCINE | ALLEN, MICHAEL D | — |
| 18345379 | METHODS FOR IN VITRO TRANSCRIPTION | MEYERING, SHABANA SHABBEER | — |
| 17737884 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | CRUM, MARY ABOU NADER | — |
| 17619882 | IMPROVED IN VITRO TRANSCRIPTION PURIFICATION PLATFORM | SCHACHERMEYER, SAMANTHA LYNN | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1612 | 1 |
| 1671 | 1 |
| 1635 | 1 |
| 1657 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18984131 | METHOD OF LYOPHILIZING LIPID NANOPARTICLES | TCHERKASSKAYA, OLGA V | 1615 | §112 | Non-Final OA | — | Pending | Dec 17, 2024 |
| 18660219 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | SHOMER, ISAAC | 1612 | §102§103§112Other | Non-Final OA | — | Pending | May 09, 2024 |
| 18614077 | LIPID NANOPARTICLES ENCAPSULATION OF LARGE RNA | SASAN, ARADHANA | 1615 | DP | Final Rejection | — | Pending | Mar 22, 2024 |
| 18427625 | METHODS AND COMPOSITIONS FOR QUADRIVALENT INFLUENZA VACCINE | ALLEN, MICHAEL D | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18345379 | METHODS FOR IN VITRO TRANSCRIPTION | MEYERING, SHABANA SHABBEER | 1635 | §103 | Final Rejection | — | Pending | Jun 30, 2023 |
| 17737884 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | CRUM, MARY ABOU NADER | 1657 | §102§103§112DP | Non-Final OA | — | Pending | May 05, 2022 |
| 17619882 | IMPROVED IN VITRO TRANSCRIPTION PURIFICATION PLATFORM | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §103 | Non-Final OA | — | Pending | Dec 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArcturus Therapeutics Inc. has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Olga V Tcherkasskaya has the most, with 1 of Arcturus Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
